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KESAN ANTIKANSER MADU TUALANG KE ATAS KARSINOMA 
KELENJAR MAMARI ARUHAN 7,12-DIMETHYLBENZ(α)ANTHRACENE 
(DMBA) DALAM TIKUS 
 
ABSTRAK 
 
Madu Tualang (TH) dilaporkan mempunyai kesan antiproliferatif dan 
mengaruhkan apoptosis terhadap beberapa jenis titisan sel kanser. Kajian telah 
dijalankan untuk mengkaji kesan madu Tualang terhadap pembentukan dan 
perkembangan karsinoma mamari aruhan 7,12-dimethylbenz(α)anthracene (DMBA) 
dalam tikus. 
Satu kajian persediaan telah dijalankan untuk menetapkan dos optimum DMBA 
untuk aruhan kanser. Pemberian sebanyak satu dos 20 atau 25 mg DMBA kepada tikus 
betina berumur 45 hingga 48 hari dengan berat badan masing-masing kurang atau lebih 
daripada 120 g menghasilkan 50% insiden karsinoma. Seterusnya, 40 ekor tikus aruhan 
DMBA dibahagikan secara rawak mengikut blok kepada empat kumpulan; Kumpulan 1, 
2, 3 dan 4 dan menerima 0 (kawalan), 0.2, 1.0 or 2.0 g/kg TH setiap hari bermula pada 
keesokan harinya sehingga 150 hari. Nodul tumor payudara yang terbentuk diperiksa 
dua kali seminggu dan berat badan diambil sekali seminggu. Pada hari ke-151, darah 
telah diambil untuk penentuan jumlah kiraan limfosit dan kemudiannya semua tikus 
dibunuh. Semasa autopsi, insiden, kriteria, jumlah, berat dan isipadu tumor telah 
ditentukan. Tumor kemudiannya diperiksa secara histopatologi berserta penentuan 
indeks apoptosis dan paras faktor pertumbuhan endotelium vascular. 
xvii 
 
Pemerhatian klinikal menunjukkan Kumpulan 2 mempunyai peratusan insiden 
tumor tertinggi (75%) manakala Kumpulan 4 yang terendah (42.9%). Kumpulan 4 juga 
mempunyai tempoh kependaman tumor paling pendek (Hari ke-101 ± 18) manakala 
Kumpulan 3 yang terpanjang  (Hari ke-140 ± 4). Kumpulan yang menerima TH (THG) 
menunjukkan peratusan penambahan berat badan sebenar yang lebih rendah berbanding 
kawalan (p = 0.012). Tumor untuk THG mengalami penambahan saiz yang lebih lambat 
dan min yang lebih kecil (≤2 cm3) berbanding kawalan (≤8 cm3). Jumlah tumor semasa 
autopsi bagi THG adalah lebih sedikit (12, 5 dan 7 tumor untuk Kumpulan 2, 3 and 4) 
berbanding kawalan (14 tumor). Jumlah keseluruhan berat dan isipadu tumor per tikus 
juga lebih rendah bagi THG. Berat tumor untuk Kumpulan 2 dan isipadu tumor untuk 
Kumpulan 4 adalah dengan signifikannya lebih rendah berbanding kawalan (masing-
masing p = 0.048 dan p = 0.018).  
Pemeriksaan histolopatologi menunjukkan majoriti tumor kumpulan TH adalah 
bergred rendah (1 dan 2) berbanding kawalan (gred 3). Tumor yang dirawat TH 
menunjukkan kurang bilangan karsinoma duktus in situ (DCIS) dengan purata 4, 8 dan 9 
DCIS bagi Kumpulan 2, 3 dan 4 manakala 14 DCIS untuk kawalan. Sel-sel kanser THG 
kelihatan lebih tersusun, bersaiz dan berbentuk yang lebih sekata dan mempunyai nuklei 
yang lebih padat. Indeks apoptosis (AI) menunjukkan corak peningkatan dengan 
pemberian dos TH yang lebih tinggi, manakala aras faktor pertumbuhan endotelium 
vaskular (VEGF) menunjukkan corak penurunan bagi kanser THG berbanding kawalan. 
Tiada perbezaan yang signifikan bagi jumlah kiraan limfosit di kalangan kumpulan tikus 
yang mempunyai kanser atau tiada kanser. 
xviii 
 
Kajian menunjukkan bahawa pemberian madu Tualang diberi bermula sehari 
selepas pemberian DMBA untuk tempoh selama 150 hari dengan positifnya mengubah 
perkembangan karsinoma mamari aruhan DMBA pada tikus. Maka, adalah dicadangkan 
supaya kajian terperinci mengenai penggunaan madu lebah Tualang sebagai agen 
profilaktik dan terapeutik bagi kanser payudara dikalangan manusia dilaksanakan. 
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ANTICANCER EFFECTS OF TUALANG HONEY ON 7,12-
DIMETHYLBENZ(α)ANTHRACENE (DMBA)-INDUCED MAMMARY 
CARCINOMA IN RATS 
 
ABSTRACT 
 
Tualang honey (TH) has been reported to have antiproliferative effect and 
induces apoptosis in various cancer cell lines. The present study was conducted to 
evaluate the effects of TH on the initiation and progression of 7,12-
dimethylbenz(α)anthracene (DMBA)-induced mammary carcinoma in rats.  
A preliminary study was conducted to establish the optimum DMBA dose for 
cancer induction. Single administration of 20 or 25 mg DMBA to 45 to 48 days old 
female rats with bodyweight of less or more than 120 g respectively was able to induce 
50% carcinoma incidence. Later, 40 DMBA induced rats were block randomized into 
four groups; Group 1, 2, 3 and 4 and given 0 (control), 0.2, 1.0 or 2.0 g/kg/day of TH 
respectively starting the next day for 150 days. Breast tumor nodules were assessed 
twice weekly and body weight was measured once a week. On Day 151, blood was 
withdrawn for analysis of total lymphocyte count and later the animals were euthanized. 
During autopsy, the tumor incidence, criteria, amount, weight and volume were 
assessed. Tumors were then subjected for histopathological examination and 
determination of apoptosis index and vascular endothelial growth factor level. 
Clinical observation revealed that Group 2 presented with the highest percentage 
of tumor incidence (75%) whereas Group 4 with the lowest (42.9%). Group 4 also had 
xx 
 
the shortest tumor latency period (Day 101 ± 18) while Group 3 had the longest (Day 
140 ± 4). TH-treated groups (THG) showed lower percentage of actual body weight gain 
than control (p = 0.012). Tumors in THG presented with slower size increment and 
smaller mean tumor size (≤2 cm3) compared to control (≤8 cm3). Number of tumors 
during autopsy in THG was lesser (12, 5 and 7 tumors for Group 2, 3 and 4 respectively) 
than control (14 tumors). Total tumor weight and volume per animal were also lower in 
THG. Tumor weight in Group 2 and tumor volume in Group 4 were significantly lower 
than control (p = 0.048 and p = 0.018 respectively).  
Histopathological examinations showed majority of TH-treated tumors were of 
grade 1 and 2 compared to control (grade 3). TH-treated tumors had less ductal 
carcinoma in situ (DCIS) with average per tumor of 4, 8 and 9 DCIS for Group 2, 3 and 
4 respectively whereas 14 DCIS for control. THG cancer cells appeared more orderly 
arranged, more uniform in size and shape and had denser nuclei. Apoptotic index (AI) 
was noted to be in elevated pattern towards treatment of higher TH dose, while vascular 
endothelial growth factor (VEGF) showed pattern of reduced level in THG cancers 
compared to control. No significant difference was noted in total lymphocyte count 
among groups of rats with or without cancer.   
This study shows that TH administered starting a day after DMBA 
administration and continuously for 150 days was positively modulating the progression 
of DMBA-induced mammary carcinoma in rats. Hence, TH should be investigated 
further as prophylactic and therapeutic agent against breast cancer in human.  
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CHAPTER 1 
 
INTRODUCTION 
 
Breast cancer or mammary carcinoma is a type of disease caused by 
uncontrollable growth of ductular epithelium of the breast. The mass of cancerous cells 
forms a lump and could metastasize to other organs. The incidence of breast cancer in 
women is alarmingly high especially in developed countries. In Malaysia, breast cancer 
is the most frequently diagnosed cancer among women which represents 31.3 % of all 
female cancers from 2003 to 2005 (Lim et al., 2008).  
Early diagnosis and treatment of breast cancer is very important for a successful 
disease recovery. Nonetheless, the common scenario in Malaysia and several other 
developing countries is that the cancer patients abscond or present late for hospital 
treatment. The deterring factors are usually related to social and cultural perception of 
breast cancer, such as preference for noninvasive traditional or alternative therapy over 
modern treatment which could be related to fear for surgery, chemotherapy or 
radiotherapy, living in doubt or denial of the disease, or having financial problem 
(Sandelin et al., 2002, Hisham and Yip, 2004, Clegg-Lamptey et al., 2009). Often, by 
the time the patients seek hospital treatment, the cancer is already at advanced stage of 
III or IV which is difficult to cure. 
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Therefore, one of the best options to solve the problem is to prevent the disease 
from occurring. For that matter, it is important to determine the factors that could 
contribute to the prevention of breast cancer initiation and development. 
Chemoprevention of cancer involves the use of natural or synthetic chemicals to arrest 
or reverse the carcinogenic process (Tsao et al., 2004). One of the experimental 
approaches in search of new chemopreventive agent for breast cancer is by assessing the 
effect of the test substance on chemically-induced mammary carcinoma in an animal 
model (in vivo). It is a suitable model to study the potential new therapeutic agent in a 
wide-scope view involving physiological processes in a living body. DMBA which is 
the short form for 7, 12-dimethylbenz(α)anthracene has been commonly used to induce 
mammary carcinoma in rats for testing of various potential substances in preventing or 
curing breast cancer.  
 Honey has been known for centuries for its medicinal value and health 
promoting properties. This notion was supported by various religious beliefs. Back in 
ancient times, Egyptians, Assyrians, Chinese, Romans and Greeks have been known to 
use honey for the treatment of wounds and diseases in guts (Zumla and Lulat, 1989). In 
Islam, as stated in the Holy Qur‟an, Surah Al-Nahl (The Bee), verses 68 to 69, honey 
has been emphasized as medicine for various kind of diseases of mankind. For that 
reason, a type of Malaysia‟s own local honey called Tualang honey (TH) has been 
chosen for the study and is aimed to discover its potential in prevention of breast cancer 
development in animal model. 
Recent in vitro studies have shown that TH possesses significant anticancer 
effect against breast and cervical cancer (Fauzi et al., 2010) and antiproliferative effect 
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against oral cancer (Ghashm et al., 2010). TH is also known to possess strong 
antioxidant activity (Mohamed et al., 2010) which could largely contribute to the 
prevention of breast cancer development. Therefore, effects of TH administration on the 
tumor growth characteristics were evaluated in the present study. Among the parameters 
included in the assessment were morphological features and tumor grades. Histological 
grading was performed as it is an important prognostic factor for the disease (Ignatiadis 
and Sotiriou, 2008). It has been reported that mammary carcinomas in rats share similar 
features with the adenocarcinomas in human (Russo and Russo, 2000, Singh et al., 
2000) 
The effects of TH administration on the apoptotic and angiogenesis activity of 
the mammary tumor were also evaluated. Apoptosis or “programmed cell death” is a 
process of removing damaged cells without disturbing normal cells. Apoptotic activity is 
a good indicator to assess the efficacy of TH which could be used as a target in the 
cancer treatment. Angiogenesis is responsible for the formation of new blood vessel 
from pre-existing vascularization in order to support the tumor growth and metastases 
(Harris, 2003). An agent with anti-angiogenic property could play a role in suppressing 
the tumor development. For that matter, an angiogenic growth factor known as vascular 
endothelial growth factor (VEGF) which could be detected in breast cancer (Harris et 
al., 1996) was measured quantitatively in order to assess the aggressiveness of the 
tumor.  
Neoplastic cells occurrence somehow could be explained by suppressed, 
inadequate or malformed state of spontaneous immune response, modifying the normal 
T and B lymphocytes roles to fight against the abnormal cells formation and 
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development. Honey is however proven to cause an increase in proliferation of both B 
and T lymphocytes in vitro (Abuharfeil et al., 1999). This gives a good opportunity to 
test if TH has the same positive effect in in vivo study in a way to improve the immune 
defense system by destroying and/or eliminating the tumor cells. Assessment of 
circulating lymphocytes in the peripheral blood is a good parameter as it could represent 
capability of mammary cancer-induced subjects to produce immunity cells from the 
effect of TH administration. 
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1.1 Objectives 
 
1.1.1 General objective 
The general objective of this study was to evaluate the efficacy of Tualang honey 
in preventing the initiation and progression of DMBA-induced mammary carcinoma in 
rats.  
 
1.1.2 Specific objectives 
a) To study the effect of TH administration on the incidence, latency, 
multiplicity, weight and volume of DMBA-induced tumors in rats. 
b) To determine the effect of TH administration on the grades and morphology 
of DMBA-induced breast carcinomas in rats.  
c) To determine the effect of TH administration on apoptotic cell death in 
DMBA-induced breast carcinomas in rats.  
d) To determine the effect of TH administration on rat‟s vascular endothelial 
growth factor (VEGF) in DMBA-induced breast carcinomas in rats.  
e) To determine the effect of TH administration on the total lymphocyte count 
of rats induced with DMBA. 
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1.2 Significance of research 
This study could provide information on the benefits of Tualang honey in 
preventing breast tumor formation and development. Further study could be done to 
identify the effective compound in TH that contributes to its beneficial effects. 
 
1.3 Hypothesis 
Tualang honey is capable of preventing the initiation and progression of DMBA-
induced mammary carcinoma in rats. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Breast cancer  
 
2.1.1 Background 
 In general, cancer is defined as a group of abnormal cells that grow and divide 
without control. Originated from the breast tissue area, breast cancer or mammary 
carcinoma which usually occur in women resulted from the new formation of cells 
(neoplasm) that are most commonly from ducts and lobules area which undergo rapid 
transformation and growth and thus eventually causing the formation of lump or mass, 
known as tumor (Damjanov, 2006). Tumors can be benign or malignant. Benign tumors 
can be identified based on characteristics such as localized growth and no distant spread 
i.e. metastasis to other organs. On the other hand, malignant tumors, known as cancer 
involve cells infiltrate or metastasis to other parts of the body such as to lymph nodes, 
bones, liver, lungs and brain via blood vessels and lymphatic channels (Crowley, 2007). 
Metastasis can compromise the normal function of the involved tissue or structure.  
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2.1.2 Prevalence 
Breast cancer as the commonest type of cancer among women of all races in 
Malaysia was represented by age-standardized rate of 47.4 per 100,000 women 
compared to the incidence of breast cancer in men of only 1.2 per 100,000 men. 
According to the same source which was mainly based on cases in Peninsular Malaysia 
from 2003 to 2005, the incidence was highest among women of age between 50 to 60 
years old, except for Indians which has the highest incidence among women aged above 
60 years old. However, the incidence of breast cancer among women in Malaysia is still 
lower than most Western countries such as USA, Canada, England, Netherland and 
Denmark (Lim et al., 2008). 
 
2.1.3 Risk factor 
 Breast cancer is believed to be caused by a single or multiple endogenous and 
exogenous factors. The chances of getting breast cancer is higher in older age women 
especially those reaching the age of menopause which is of 50 years old and above 
(Marchant, 1982). The risk is higher for women with earlier age of her first menstrual 
period (menarche) especially before the age of 12, experienced menopause after the age 
of 55, never had or late in having a full-term pregnancy which is approximately after the 
age of 35, never breast fed or having larger area of dense mammary tissue appeared on 
the mammogram assessment (Hsieh et al., 1990, Kelsey et al., 1993, Boyd et al., 2002). 
The risk is also higher if there is any immediate family member or first degree relatives 
including mother, sister or daughter had breast cancer, especially if they had the disease 
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before the age of 50 (Colditz et al., 1996). The same risk also implies if they had history 
of ovarian cancer (McPherson et al., 2000). 
 Other than that, personal health history of having benign breast lump or certain 
types of abnormal breast disease such as atypical hyperplasia also increases the risk of 
breast cancer (London et al., 1992). Women who had a history of breast cancer in one 
breast have a risk of developing cancer in the other breast (Helmrich et al., 1983). 
Detection of gene mutation on breast cancer-related genes such as breast cancer 
susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2) and tumor 
suppressor gene p53 in the genetic make-up substantially increases the chance of getting 
breast cancer (Martin and Weber, 2000).  Other exogenous factors that increase the risk 
of breast cancer include long term treatment of oral contraceptive pills and menopausal 
hormone replacement therapy (Pike et al., 1993), undergone radiation therapy to the 
chest before the age of 30, being overweight or obese after menopause and last but not 
least, practicing unhealthy lifestyle with lack of physical activity and excessive 
consumption of high-fat, low fiber diet and alcohol beverages (Howe et al., 1990). 
 
2.1.4 Structure of the human breast 
The anatomy of a normal woman‟s breast is comprised of two breasts on the 
anterior chest wall. Each breast is structured by 15 to 20 lobes that each has smaller 
sections of lobules. Lobules contain milk-producing glands and ducts (lactiferous duct) 
that connect the lobules to the nipple as a passage for breast milk deliverance. Fatty 
tissue and fibrous connective tissues (stroma) that contain blood capillaries and nerves, 
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surround both lobule and ductal units (Figure 2.1). Breasts are also surrounded by a 
network of lymph vessels that drains into lymph nodes at the chest wall and underarm 
(axilla) area (Ganshow et al., 2004). 
The lobular structure is comprised of ducts that are divided into club-shaped 
terminal end buds and these buds later cleave into two smaller structures of alveolar 
buds. A cluster of alveolar buds that surrounds the terminal ducts forms the lobule type 1 
(Lob 1) or also known as terminal ductal-lobular unit (TDLU) or virginal lobule. TDLU 
is the functional unit of human mammary gland and it contains abundance of highly 
proliferative stem cells population (Russo and Russo, 1978). The other type of lobules, 
namely lobule type 2 (Lob 2) and type 3 (Lob 3) are the gradual sprouting of the alveolar 
buds, which are also called as ductules. Progressive branching of Lob 2 and 3 from Lob 
1 makes them more developed and differentiated (Figure 2.2). Lobule type 4 (Lob 4) 
which is present during lactational period of the mammary gland is the most 
differentiated lobule structure. In nulliparous women, more undifferentiated structure of 
lobule type 1 and terminal ducts are found; which will remain throughout their 
nulliparous life with only scarce appearance of Lob 2 and 3 and complete absence of 
Lob 4. On the other hand, breast of parous women are predominated with fully 
developed and differentiated Lob 3 since the breast lobules reached its maximum 
development during pregnancy after a rapid progression from Lob 1 to Lob 2 and finally 
to Lob 3 (Russo and Russo, 2004). 
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Figure 2.1: Anatomy of a normal human breast. The figure is illustrated in cross-
sectional view as adapted from Ali and Coombes (2002). 
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Figure 2.2: Lobular structure in human breast. This diagram of lobular structure is 
showing Lob 1, 2 and 3 in the human breast (adapted from Russo and Russo, 2004).  
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2.2 Basic carcinogenic process of breast cancer 
All pathogenesis of cancer started with multistep process of carcinogenesis 
including the pathogenesis of breast cancer. It is well known that carcinogenesis is the 
result of interaction between exogenous (environmental) factors and endogenous 
process, which triggers the genetic or epigenetic alteration of multiple genes 
(Kyrtopoulos, 2006). Most common scenario is the exposure of somatic cells or 
occasionally germ or stem cells to various exogenous factors, either chemically, such as 
exposure to polycyclic aromatic hydrocarbon (PAH) substance, or physically, such as 
ionizing radiation causing the stem cells to undergo random mutations.  
Genes most commonly affected by the mutation are called proto-oncogenes and 
tumor suppressor genes. The activation of proto-oncogenes into oncogenes results in the 
production of proteins which increase the transformation and proliferation of 
genetically-insulted tumor cells. Altered tumor suppressor genes (e.g. BRCA1, BRCA2, 
and p53) as occurred in most hereditary or familial breast cancer, lose its sole function to 
prevent tumor formation of blocking or limiting the cell growth (McPherson et al., 2000, 
Croce, 2008). 
Mutated genes in the stem cell causes inheritable spontaneous changes in DNA 
structure and affects the DNA replication and subsequent cell division. This will cause 
imbalance to the rate of cell proliferation and cell death thus alters the normal 
homeostasis environment. The increased cellular multiplication of the mutated cells or 
so-called „initiated cells‟ with reduced programmed cell death mechanism (apoptosis) 
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for many cell generations causes the formation of excessive amount of new abnormal 
cells, later known as neoplasia (Bertram, 2000).  
Carcinogenesis can be simplified into three main stages; initiation, promotion 
and progression. Initiation stage is when the cells are induced with various carcinogens 
into irreversible genetically altered or DNA-damaged cells consequent to the mutation 
activation. Usually, only multiple genes mutation can result in cancer formation since 
the huge damage will causes many disruption of bodily restore system including its own 
DNA repair mechanism. During promotion, the altered cells are stimulated to grow and 
proliferate faster to form a new population of cells of which is usually benign or 
preneoplastic lesion. Hormones such as estrogen are known as one of the promoter in 
human breast cancer. The progression stage involves more additional mutations and 
other heritable changes to the genetically-fragile tumor cells for transformation into 
malignant cells (Barrett, 1993). After the individual first exposure to the carcinogens, it 
usually takes many years or even decades for the promotion and progression to complete 
before the cancers are formed (Tsao et al., 2004). 
 
2.2.1 Pathogenesis of human breast cancer 
The site of origin for breast cancer has been acclaimed to arise from TDLU that 
comprises the most undifferentiated structure unit of Lob 1 which is also the origin site 
for the most common type of malignancy in human breast known as invasive ductal 
carcinoma (Russo and Russo, 1978, Wellings et al., 1980, Russo et al., 1998). The high 
proliferative activity and fragility upon genetic alteration by exogenous mutagenic 
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influence of Lob 1 makes it highly susceptible for preneoplastic and neoplastic process 
(Russo and Russo, 1978).  
When the cells are mutagenic, instead of progressing into Lob 2 type of cells, Lob 
1 cells congregated in ductules and progressed into atypical type of TDLU to become 
the precursor for the neoplastic transformation. The preneoplastic lesion is later 
developed into ductal carcinoma in situ (DCIS) and eventually turns into aggressive type 
of invasive ductal carcinoma of which cells began to metastasize to other parts of the 
body. More differentiated lobule structures of Lob 2 and 3 are prone to pathogenic 
changes under carcinogenic influence as well. Lob 2 originates the formation of atypical 
lobules once it progress into lobular carcinoma in situ and later into metastatic lobular 
invasive carcinoma. Lob 3 tends to progress into more benign type of lesion compared to 
other type of lobules such as into hyperplastic lobules, fibroadenomas, apocrine cysts, 
sclerosing adenosis and other type of adenomas. Most differentiated Lob 4 on the other 
hand seems to show the highest resistance against neoplastic formation as it usually 
progressed into lactating adenomas only (Russo and Russo, 1978). 
 
2.3 Chemoprevention studies 
 The general objective of chemoprevention is to interfere with the basic process of 
carcinogenesis by chemical agents that may block the initial neoplastic induction or 
prevent the progression of transformed cells into malignant type of neoplasm. Another 
objective is to prevent development of second primary tumors that may arise from 
people who has been cured from the initial cancer (Tsao et al., 2004). The multistep of 
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carcinogenesis process over a long period of time gives the possibility for intervention of 
natural or synthetic chemopreventive agents at various specific stages of carcinogenesis. 
The long latent period of cancer formation might be the reason why the high occurrence 
of breast cancer is among the elderly women of whom might have been exposed to 
potential carcinogenic agent at their early lifetime.  
In brief, the concept for application of this theory is to give the potential 
chemopreventive agents to the subjects who have been exposed to carcinogen during 
their early age. Many chemoprevention studies to date have applied this principle. The 
potential agents can be given either before or shortly after exposure to the carcinogen, 
depending on the objectives of the study. Results from the experimental model can later 
be classified as an anti-initiating agent if the intervention is during the initiation stage or 
anti-promoting agent if the intervention is during the promotion and progression of 
carcinogenesis. The intervention must have the purpose of enhancing or improving the 
protective physiological mechanism against the disease (Mehta, 2000). Figure 2.3 shows 
the overview of appropriate intervention time of chemopreventive agents at specific 
stage of carcinogenesis as proposed by Garro et al. (1992) and Mehta (2000). 
 
 
 
 
 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Stages of carcinogenesis and intervention by chemopreventive agent. 
The three main stages in carcinogenesis could be intercepted with chemopreventive 
agent at two probable time points corresponding to the respective stages. 
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With the basic knowledge that normal cells can be transformed chemically into 
cancer phenotype, experimental basis for chemoprevention studies is categorized into in 
vitro or in vivo. In vitro or cell culture method is a famous method in breast cancer 
studies that involves growing specific cell lines, e.g. MCF-7 or MDA-MB-231 for breast 
cancer, in a strictly-controlled environment. This method is usually chosen for 
experiment that focused on the mechanism of action of specific cells through their 
molecular pathway. For studies of finding new drugs or drug development that involves 
monitoring full scale pharmacological effects of drug to the body system in aspects of 
immune response, tissues and protein signaling, angiogenesis and apoptosis reaction, in 
vivo is the most suitable model since it is able to display most physiological process of a 
living animal. Besides, the multiple stages of carcinogenesis are only possible to be 
observed in animal model (Gupta and Kuperwasser, 2004). 
 
 
2.4 Breast cancer induction in animal model using DMBA 
 It is crucial to apply a study model that resembles the physiopathology of the 
human cancer condition. In vivo model that uses rodents, specifically by using rat is a 
very useful method since its mammary gland is highly susceptible to chemical 
carcinogen, able to develop spontaneous mammary carcinoma, and most importantly, its 
pathogenesis and origin site of mammary cancer is quite similar to that of human (Russo 
and Russo, 1978, Medina, 1996).  
 A genotoxic agent called 7,12-dimethylbenz(α)anthracene (DMBA) has been 
recognized as a potent agent to elicit mammary carcinoma in rodents. A successful 
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induction of breast cancer in rodent depends on the species, strain and age of the host, 
along with its reproductive history, hormonal status and diet. Most of the mammary 
malignancy developed in female rats with DMBA induction is hormone-dependent and 
arise from mammary glandular epithelium later known as adenocarcinoma which is a 
type of malignancy most commonly diagnosed in human (Russo and Russo, 1996a).  
 Rat of Sprague-Dawley strain is the top choice for its high susceptibility to 
DMBA induction compared to other strains (Isaacs, 1986). Single administration of 
DMBA at appropriate dose through oral or gastric gavage is sufficient for a rat to 
develop mammary carcinoma (Huggins et al., 1961). The administration should be done 
within a specific window of age which is between 40 to 60 days of age (Russo and 
Russo, 1978, Rogers and Lee, 1986). It is crucial to use nulliparous rats for DMBA 
induction since parous rats with more differentiated structure of lobular unit develop 
some resistance against the formation of chemically-induced mammary carcinoma. 
 
2.4.1 Structure of mammary system in rats 
 The mammary glands of a female rat are subcutaneously aligned in ventrolateral 
position from the cervical to the inguinal regions forming six pairs of glands with one 
nipple for each gland (Figure 2.4). The first pair of gland is at the cervical region, both 
the second and third pairs are at the thoracic region and the other three pairs are at the 
abdomino-inguinal region (Russo and Russo, 1996a). Whole mount preparation of 
complete mammary organ shows complex branching of stroma and parenchyma forming 
duct structures which extends from the nipple into the fat pad. The primary or main 
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branch of duct is called lactiferous duct from which it continuously branch into 
secondary ducts and further up to six generation of branches. The further branches are 
smaller ducts, or known as ductules. The end structures of the ductules are later 
classified into several types; alveolar buds (AB), blunt end buds or terminal end buds 
(TEB) (Russo and Russo, 1978, Masso-Welch et al., 2000). 
 The mammary duct is a tubule structure with walls of two types of cells; epithelial 
cells that line the lumen and the inner layer of myoepithelial cells. The basement 
membrane separates the parenchyma layers from the stroma (connective tissue). During 
the differentiation process of rat mammary gland, immature state of club-shaped TEB 
differentiates into AB and finally into matured lobules structure. TEB is composed of 
three to six layers of highly proliferating epithelial cells and responsible for branching 
and elongation of the duct. Cavitations of TEB causes formation of wide-hollow duct 
called the blunt end buds or terminal ductule (TD), which is the target site of carcinogen 
in older animals for the development of carcinoma (Masso-Welch et al., 2000).  
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Figure 2.4: Position of mammary glands in the female rat. The glands are shown to its 
maximum extent lateral and ventrally at specific position in the body. The gland is seen 
oriented from the six-paired nipples. Cervical, thoracic and abdomino-inguinal regions 
are stated when denoting the position of tumor on the rat mammary pad. 
 
 
 
22 
 
 The density of TEB is highest when the rat is approximately 21 days old and 
decrease sharply until 63 days old, and slowly until 84 days old. This decrease is either 
due to the change from TEB into AB and later to lobules, or TEB evolution into TD. The 
amount of AB on the other hand, increases steadily until it reaches a plateau state at the 
age of between 70 to 84 days old  (Russo and Russo, 1978).  
 
2.4.2 Pathogenesis of rat mammary carcinoma 
 Administration of DMBA to the rats when the amount of proliferating TEB is at 
the peak and actively differentiating into AB causes the highest incidence of mammary 
carcinoma and number of tumor formation (Russo et al., 1983b). After the exposure to 
DMBA, instead of progressing into AB, the lining epithelium of TEB undergoes 
intraductal proliferation (IDP) thus becoming larger in size. This continuous and rapid 
DNA synthesis (Russo et al., 1983a) and cell proliferation causes further increase in size 
and later known as microtumors. With the right microenvironment, these tiny tumors 
will enlarge and become a more aggressive type of adenocarcinoma. In correlation with 
the human mammary gland, TEB in young virgin rats is equivalent to TDLU (Lob 1) 
structure in nulliparous women (Russo and Russo, 1978, Russo and Russo, 1996a), 
which is believed to be the origin site of breast cancer. Therefore, it is proven that rat 
mammary carcinoma model is sufficient to mimic the breast carcinoma disease in 
human. 
 However, not all carcinogen-exposed TEB will turns into IDP. This minority 
group of TEB is still able to progress into AB. In certain occasion, some TEBs are 
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already differentiated into AB at the time of DMBA exposure. These ABs would either 
remain normal or proliferate at moderate pace forming more benign type of tumor such 
as adenomas, cysts, or undergoes lumen dilatation, thus giving rise to hyperplastic 
alveolar nodules (HAN) (Russo et al., 1983b).  
 
2.4.3 Carcinogenicity of 7,12-dimethylbenz(α)anthracene (DMBA)  
 DMBA is a polycyclic aromatic hydrocarbon (PAH) substance, an environmental 
pollutant that can be found basically from afterburning products and certain industrial 
process such as tobacco smoke, industrial and domestic oil furnaces, gasoline and diesel 
engines. For laboratory purposes, DMBA is usually produced synthetically. In order to 
exert its biological activity, DMBA needs to undergo metabolic activation which is quite 
contrary to other types of carcinogens that commonly act as direct-acting carcinogen, 
such as ionizing radiation and another type of chemical carcinogen used for mammary 
carcinoma induction called N-methyl-N-nitrosourea (MNU).  
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Figure 2.5: Chemical structure of DMBA (Melendez-Colon et al., 1999). 
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2.4.4 Metabolic activation of DMBA 
 In rats, DMBA is metabolized in hepatic microsomes through oxidation and 
hydroxylation by P450 monooxygenase enzymes into reactive electrophilic metabolites 
that includes 7-hydroxymethyl-12-methylbenz(α)anthracene, 12-hydroxymethyl-7-
methylbenz-(a)anthracene and many other diol-epoxides (Flaks et al., 1972, Yang and 
Dower, 1975). These metabolites which are responsible for the mutagenic and 
carcinogenic initiation, later bind to cellular macromolecules, particularly the DNA 
within the mammary cells especially the ones in the TEB epithelial cells (Russo et al., 
1979) forming covalent DNA adducts such as DMBA-3,4-dihydrodiol 1,2-epoxides 
(DMBADEs) (Melendez-Colon et al., 1999).  
 The formation of DMBA-DNA adduct causes impairment to the DNA structure 
itself, amplified with the impaired DNA repair mechanism, thus proper replication 
cannot be done and the abnormal DNA will be the starting point of mutagenesis. 
Oxidative metabolism of carcinogens also leads to the formation of reactive oxygen 
species (ROS) such as hydrogen peroxide which is an established tumor promoter 
(Frenkel et al., 1995),  hydroxyl radicals and other free radicals that can cause oxidative 
DNA damage and stimulates the cancer initiation (Xue and Warshawsky, 2005). 
 
 
  
 
